Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease
- PMID: 9367397
- PMCID: PMC2265492
- DOI: 10.1111/j.1365-2249.1997.tb08312.x
Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease
Abstract
We have investigated the biological and therapeutic properties of a humanized anti-CD4 MoAb, hIgG1-CD4, in patients with refractory psoriasis and rheumatoid arthritis (RA). hIgG1-CD4 is a modulating, non-depleting MoAb, which induced a first-dose reaction in most patients treated. It provided brief symptomatic relief in both conditions, and psoriasis appeared easier to control with conventional agents after MoAb therapy. At the doses used, hIgG1-CD4 did not synergize therapeutically with the panlymphocyte MoAb CAMPATH-1H (C1H) in patients with RA treated sequentially with both agents. There were no serious adverse effects definitely attributable to therapy. Our results are compared with those of other CD4 MoAb studies, and factors influencing the outcome of therapy are discussed.
References
-
- Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature. 1986;320:449–51. - PubMed
-
- Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody therapy to L3T4. J Immunol. 1986;137:1127–32. - PubMed
-
- Cobbold SP, Qin S, Leong LYW, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev. 1992;129:165–201. - PubMed
-
- Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H. Infectious’ transplantation tolerance. Science. 1993;259:974–7. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
